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ABSTRACT
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high 
mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in ~20% of 
the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. 
We investigated the therapeutic impact of Omomyc, a MYC dominant negative, in a 
panel of SCLC cell lines. Strikingly, Omomyc suppressed the growth of all tested cell 
lines by inducing cell cycle arrest and/or apoptosis. Induction of G1 arrest by Omomyc 
was found to be dependent on the activation of CDKN1A, in part, through the TP73 
pathway. Our results strongly indicate that SCLC cells carrying amplification of MYC, 
MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be 
an efficient therapeutic option for SCLC patients.
INTRODUCTION
Small cell lung cancer (SCLC) is the most 
aggressive type of lung cancer with only 5% of five-year 
survival rate after diagnosis [1]. This is in part due to the 
fact that proper targeting therapies for SCLC have not 
yet been developed. In SCLCs, only a limited number of 
genes, such as TP53 and RB1, are recurrently mutated 
[2–5]. One of the MYC family genes, MYC, MYCL or 
MYCN, is amplified and overexpressed in ~20% in a 
mutually exclusive manner and represents the most 
prominent activating oncogene alteration in SCLC [2, 
4,6]. Therefore, MYC proteins are strong candidates 
as therapeutic targets in patients with SCLC. However, 
the following crucial points must be taken into account. 
In mice, functional inactivation of TP53 together with 
RB1 is sufficient for the development of SCLC, and 
MYCL amplification occurs during SCLC progression 
[7, 8]. Similarly, in humans, MYC amplification is also 
likely to occur during SCLC progression [2,4, 6]. While 
reconstitution of either TP53 or RB1 induces G1 arrest 
and apoptosis in human SCLC cell lines [9, 10], it is not 
clear whether MYC suppression is sufficient to inhibit 
SCLC cell growth. Consequently, if the growth of human 
SCLC cells is not dependent on amplified MYC family 
genes, MYC suppression would not be sufficient to have 
any therapeutic effect. In several mouse models of MYC-
driven cancers, tumor regression by MYC suppression 
was hampered by the concomitant repression of TP53 or 
RB1 proteins, which highlighted the relevance of intact 
TP53 and RB1 pathways for the treatment of cancer by 
MYC targeting [11–13]. In addition, since MYC proteins 
are overexpressed in SCLC cells, higher dose of MYC 
inhibitor administration would be required than in 
cancer cells without MYC family genes amplification. 
Alternatively, it is also possible that MYC suppression 
could be highly effective if SCLC cells are addicted to the 
expression of amplified MYC family genes.
Mutually exclusive amplification of the three 
MYC family genes and the concurrent expression of two 
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or three MYC family genes together, even though only 
one of them is amplified [14], imply the convenience 
of a common suppressing agent to all MYC proteins, 
MYC, MYCL and MYCN, to inhibit the growth 
of SCLC cells by MYC inhibition. MYC proteins 
are transcription factors with highly conserved and 
functionally important regions organized in a similar 
manner among the three paralogs [15]. DNA-binding 
activity depends on a ~100 amino-acid carboxy-terminal 
region comprising the basic helix-loop-helix leucine 
zipper (bHLH-LZ) domain that confers MYC proteins 
a highly specific interaction with another factor, MAX. 
The heterodimer MYC-MAX binds DNA at E-Box 
sequences to drive transcription of numerous target 
genes. Furthermore, the MYC-MAX dimeric bHLH-LZ 
region forms a platform for the binding of other factors, 
such as MIZ1 (ZBTB17), to repress transcription of a 
set of genes which share the initiatior (Inr) element at 
their promoter region [16]. Intriguingly, it has been 
recently reported that MAX-inactivating alterations 
occur in ~6% of SCLCs in a mutually exclusive manner 
to amplification of MYC family genes, highlighting 
the relevance of MYC pathway in SCLC progression 
[17]. Soucek et al. developed a dominant-negative 
MYC, termed Omomyc, containing MYC bHLH-
LZ domain with four amino acid substitutions that 
confer high binding affinity to both MYC and MAX, 
as well as MYCN [18–20]. By competitive binding to 
both MYC and MAX, Omomyc prevents MYC-MAX 
heterodimerization and their interaction with the E-box. 
Consequently, overexpression of Omomyc inhibits the 
binding of MYC to DNA and transcription of MYC 
target genes [20, 21]. Omomyc induces apoptosis 
and/or mitotic defects in MYC-driven papillomatosis 
[21], lung adenocarcinoma [22, 23], SV40-driven 
insulinoma [24], and glioblastoma [25]. Therefore, 
Omomyc is an efficient inhibitor of both MYC and 
MYCN. Although inhibition of MYCL by Omomyc has 
not been investigated, based on the similarity of MYCL 
with MYC/MYCN in protein structure, Omomyc could 
also inhibit MYCL, representing an excellent pan-MYC 
family inhibitor.
To assess the potential of amplified MYC family 
genes as therapeutic target in SCLC, we investigated the 
effects of Omomyc on MYC inhibition in a panel of SCLC 
cell lines carrying genetic inactivation of TP53 and RB1, 
as well as amplification of one of the MYC family genes. 
We show here that the inhibition of any MYC member 
by Omomyc induces cell growth arrest and/or apoptosis 
in SCLC cells even though both TP53 and RB1 are 
genetically inactivated. Notably, Omomyc also suppressed 
the growth of SCLC cells with MYCL amplification, and is 
able to interact with MYCL. Accordingly, we concluded 
that Omomyc is a pan-MYC family inhibitor, potentially 
useful for the treatment of SCLCs carrying any MYC 
family member amplification.
RESULTS
Omomyc suppresses the growth and induces 
death of SCLC cells
To investigate the functional impact of MYC 
inhibition by Omomyc in SCLC cells, we established an 
inducible Omomyc expression system in seven cell lines 
carrying amplification of MYC, MYCL or MYCN, and 
two cell lines without amplification of any MYC family 
gene (Figure 1A). Both TP53 and RB1 are genetically 
inactivated in all the cell lines (Supplementary Tables 1 
and 2), and the amounts of MYC proteins were higher in 
the cell lines carrying amplification of the respective MYC 
family gene than those without amplification of any MYC 
gene, H345 and H2107 (Figure 1B). MYC was detected 
in H2107, while none of the MYC proteins was detected 
in H345.
pTRIPZ-Omomyc-RFP contains a tetracycline 
response element and a CMV minimal promoter upstream 
the Omomyc sequence in frame with red fluorescence 
protein (RFP) coding sequence. Addition of doxycycline 
(DX) effectively induced expression of Omomyc-RFP 
fusion protein within 24 hr of culture (Supplementary 
Figure S1A), and >99% of cells showed positive RFP 
signals in 2-4 days (Supplementary Figure S1B). All 
infected cell lines expressed similar levels of Omomyc, 
except H69omo, in which its level was much higher than 
in other cell lines. Omomyc-RFP expression was not 
detected in cells cultured without DX. SCLC cell lines 
that conditionally expressed Omomyc were designated 
with the addition of “omo” to the name of each cell line.
To assess the effects of Omomyc on the growth of 
SCLC cell lines, the cells were serially cultured for two 
to three passages with and without DX (Figure 1C). Cells 
cultured without DX (- Omomyc) proliferated similarly 
to their respective parental cells. In contrast, Omomyc 
expression with DX addition (+ Omomyc) caused 
significant growth reduction in all cell lines. No toxic 
effects were observed by DX in non-infected parental 
cells (Supplementary Figure S1C). Percentages of dead 
cells were also increased in all cell lines after Omomyc 
induction (Figure 1D). Consistently, Omomyc-induced 
cells showed marked reduction in the size of culture 
aggregates (Figure 1E). Therefore, we concluded that 
Omomyc induced growth arrest and/or death in all tested 
SCLC cell lines independently of the type and extent of 
MYC family gene amplification.
Omomyc disrupts the binding of endogenous 
MYC and MYCL with MAX in SCLC cells
Omomyc has been shown to impair the DNA 
binding ability of the heterodimer MYC/MAX to the 
E-box sequence in vitro [18, 19], but there is no data 
for the effect in vivo. In addition, the interaction of 
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Omomyc with MYCL as well as the effect of Omomyc 
on MYCL is currently unknown. Since MYC proteins 
are highly expressed in the SCLC cell lines used in this 
study, we attempted to elucidate whether Omomyc binds 
to both MYC and MYCL and inhibit their binding to 
MAX in vivo. Omomyc was induced in Lu135omo and 
H2141omo cells, which express high levels of MYC and 
MYCL accompanied by MYC and MYCL amplification, 
respectively. By a co-immunoprecipitation assay, it was 
shown that Omomyc bound to endogenous MAX and, to 
a less extent, to both MYC and MYCL (Figure 2A-2C), 
and the amount of MAX bound to MYC or MYCL was 
considerably reduced in the presence of Omomyc (Figure 
2D-2F). Therefore, we concluded that Omomyc binds 
to MYC, MYCL and MAX, and efficiently hampers the 
heterodimerization of the endogenous MYC or MYCL 
with MAX in SCLC cells in vivo.
Omomyc induces cell cycle arrest and apoptosis 
in SCLC cells
Since growth suppression was observed upon 
Omomyc induction in SCLC cells, we analyzed the cell 
cycle profile of Omomyc-induced cells at several time 
Figure 1: Omomyc induces growth suppression in SCLC cells. A. Status of the MYC family genes, TP53, and RB1 in SCLC cell 
lines used in this study. mut: mutated. Predominant type of the cell cycle arrest, occurrence of apoptosis and levels of p21, p27 and p16 after 
MYC inhibition by Omomyc are shown. B. Immunoblot analysis for the expression of MYC, MYCL or MYCN in SCLC cells. Media were 
changed 24 hr before collection of the cells. C. Growth curve of SCLC cells in the presence or absence of doxycycline (DX). Cumulative 
population doubling level (PDL) was calculated by adding the PDLs of the previous passages. Data are shown as the mean ± SD of four 
counts from a single representative experiment. P-values were calculated by unpaired two-tailed t-test. *p<0.05, **p<0.01. D. Percentage of 
dead cells. E. Representative images of floating aggregates after two (Lu135omo, H2141omo, H69omo) or three (HCC33omo) passages in culture 
in the presence or absence of Omomyc. Cells were photographed using phase-contrast microscopy at 5x magnitude.
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points after DX addition. Representative results of three 
cell lines, Lu135omo, H69omo and H345omo, are shown 
in Figure 3A-3C. Differences in cell cycle distribution 
upon Omomyc expression became evident within 4 days 
of culture with DX in six out of nine cell lines (Figure 
3D). In the remaining three cell lines, HCC33omo, H526omo 
and H2107omo, differences in cell cycle distribution were 
observed after one week of culture (Figure 3D), likely 
because of their slow growth rates (Figure 1C). The 
percentage of cells in G0/G1 phase was increased, while 
those in S and G2/M phases decreased in 7 out of 9 cell 
lines (Figure 3D). In contrast, an accumulation of cells 
in G2/M phase was observed in H345omo and, to a more 
dramatic extent, in H69omo (Figure 3B-3D). Notably, the 
percentage of cells in sub-G1 phase also increased 1 or 2 
days after cell cycle arrest in 2 MYC-amplifed, 1 MYCL-
amplified, and 2 MYCN-amplified cell lines, suggesting 
the occurrence of apoptosis in these cell lines (Figure 
3A-3C and Supplementary Figure S2A). By a poly 
ADP-ribose polymerase-1 (PARP1) immunoblot assay, 
increased cleavage of PARP1 was detected in the cell lines 
with increased sub-G1 phase, supporting the occurrence 
of apoptosis in these cell lines upon Omomyc induction 
(Supplementary Figure S2B). Apoptosis was instead not 
evident in N417omo, H2141omo and H345omo.
Induction of G1 arrest by Omomyc is 
accompanied by p21 activation
Since G1 arrest was observed in the majority of 
cell lines after Omomyc induction, we next investigated 
whether it was associated with the expression of the 
cyclin-dependent kinase inhibitors p21 (CDKN1A), p27 
(CDKN1B) and p16 (CDKN2A), which are well known 
modulators of G1/S transition [26]. Cells were cultured 
in the presence or absence of DX for 3-5 days and protein 
levels were evaluated (Figure 4). The amounts of p21 
and p27 were increased in all cell lines that showed G1 
arrest by Omomyc induction, except HCC33omo (Figure 
4), where p21 was not detected in either the presence or 
the absence of DX. In contrast, the amounts of p16 were 
decreased in all cell lines, except H2107omo. p16 reduction 
could be a consequence of cell cycle arrest and/or reduced 
E2F factors activity, since CDKN2A is an E2F-target 
gene [27]. Thus, we concluded that G1 arrest induced by 
Omomyc was accompanied by p21 increase in most SCLC 
cell lines, although TP53, a critical gene for CDKN1A 
transcriptional induction, is inactivated.
The effects of Omomyc are recapitulated by 
MYC/MYCL silencing in SCLC cells
To test wheter the effects of Omomyc on SCLC 
cells were a consequence of the specific inhibition of the 
MYC pathway, MYC expression in Lu135omo cells was 
suppressed using a siRNA for MYC. The amounts of p21 
and p27, as well as the percentage of cleaved PARP1, were 
increased in Lu135omo cells by MYC knockdown (Figure 
5A). Cell growth reduction, as well as increase in cell 
death, was also observed (Figure 5B and 5C). Therefore, 
the effects of Omomyc and those of MYC inhibition by 
siRNA were very similar to each other, supporting that 
Figure 2: Omomyc disrupts Myc/MAX heterodimerization. A, B, D, E. Co-immunoprecipitations (co-IP) were carried out using 
protein extracts from Lu135omo (A, D) or H2141omo (B, E) cultured in the presence or absence of Omomyc for 20 hr, using antibodies against 
tRFP (A, B), MYC (D), or MYCL (E). C. MYC, MYCL, MAX and Omomyc co-IP band intensities were quantified and normalized to 
corresponding Input band intensities. F. MAX co-IP band intensities were quantified and normalized to corresponding MYC or MYCL IP 
band intensities. The anti-tRFP antibody was used for Omomyc immunoprecipitation since the antibody for Omomyc crossreacted with 
MAX.
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Omomyc inhibits MYC activities. Similarly, MYCL 
expression in H2141 cells was suppressed by using a 
shMYCL/RFP inducible expression vector. After 4 days of 
DX addition, the amount of MYCL was markedly reduced 
and those of p21 and p27 were increased, concomitantly 
with RFP induction (Figure 5D). Significant growth 
suppression was also observed in shMYCL treated cells 
(Figure 5E and 5F). Therefore, the effects of Omomyc 
and those of MYCL inhibition by shRNA were also very 
similar to each other, supporting that Omomyc efficiently 
inhibits MYCL activities.
G1 arrest was not induced in H69omo cells with 
low levels of Omomyc induction
Since an extremely high level of Omomyc was 
detected in H69omo in comparison with other cell lines 
(Supplementary Figure S1A and S1B), we examined 
whether G2/M arrest induced in H69omo was a consequence 
of a high level of Omomyc expression. We used low 
concentrations of DX (0.02µg/mL) to obtain Omomyc 
expression levels in H69omo comparable to those in other 
cell lines (Figure 6A-6C). Effects of Omomyc on the 
Figure 4: Omomyc induces CDKN1A and CDKN1B. A. Immunoblot analysis and B. densitometric quantification for the expression 
of p21, p27 or p16 in SCLC cells with or without DX for 3-7 days. Expression levels of p21, p27 and p16 were normalized to the levels of 
tubulin, and the ratio of DX+ / DX- is shown. Media were changed 24 hr before collection of the cells.
Figure 3: Effects of Omomyc on cell cycle progression. A–C, Representative population histograms showing the cell cycle profiles 
and the apoptotic fractions (sub-G1) of Lu135omo (A), H69omo (B) and H345omo (C) with or without Omomyc induction. x axis and y axis 
corresponds to DNA content and cell number, respectively. Sub-G1 gate is highlighted in green. The ratio of the number of cells in G1 
phase versus S plus G2/M phases is shown. D. Cell cycle profile of cells 48 hr (N417omo, Lu135omo, H446omo, H69omo), 72 hr (H2141omo), 96 
hr (H345omo), or 1 week (HCC33omo, H526omo, H2107omo) after Omomyc induction.
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growth and death of H69omo were drastically reduced 
and only small differences in cell cycle distribution and 
apoptosis were observed. However, G1 arrest was not 
observed at any dose of DX addition (Figure 6D-6F). 
Therefore, Omomyc always induces G2/M arrest and 
apoptosis in H69omo cells and does so in a dose dependent 
manner. Since G2/M arrest was also induced in H345omo 
cells, it is likely that Omomyc effectively induces cell 
cycle arrest in either G1 or G2/M phase in SCLC cells 
(Figure 1C). These results indicate that the difference in 
the mode of growth suppression was not associated with 
Omomyc levels. The mode of cell cycle arrest was not 
associated with the type of amplified and overexpressed 
MYC family gene, either, since G2/M arrest was induced 
in one of the two MYCN amplified cell lines, H69omo, and in 
one of the two cell lines without amplification of any MYC 
family gene, H345omo. However, the effect of Omomyc 
seemed to be reduced in a MYC non-amplified cell line, 
H345omo, where none of the MYC proteins were detected 
by Western Blot analysis (Figure 1B). In H345omo, neither 
apoptosis nor PARP1 cleavage was observed. In contrast, 
the effect of Omomyc in another MYC non-amplified cell 
line, H2107omo, was similar to MYC amplified cell lines. 
In H2107omo, a considerable level of MYC was expressed 
despite the lack of amplification of any MYC family gene 
(Figure 1B). Therefore, it is possible that SCLC cells with 
MYC family gene amplification and/or overexpression are 
more addicted to MYC for their growth and survival than 
the cells without MYC amplification and/or overexpression.
Induction of G1 arrest by Omomyc is dependent 
on P21 activation
We previously reported that exogenous p21 
expression induced G1 arrest in N417 cells [10], while 
it was shown that the growth of SCLC cells was not 
suppressed by over-expression of p27 [28]. Therefore, we 
next investigated whether G1 arrest and cell death induced 
by Omomyc were dependent upon p21 activation, encoded 
by the CDKN1A gene. N417omo cells, which underwent 
G1 arrest by Omomyc, and Lu135omo, which showed both 
G1 arrest and apoptosis by Omomyc, were treated with a 
siRNA for CDKN1A at the time of Omomyc induction. 
After 72 hr of induction, the amount of p21 increased in 
Figure 5: Activation of CDKN1A by knockdown of MYC or MYCL. A. Immunoblot showing MYC, p21, p27 and PARP1 
levels after 72 hr of siMYC transfection in Lu135omo cells. B, C. Number of Lu135omo cells and percentage of dead cells after 96 hr of 
transfection with control siRNA (siCtrl) or siMYC. D. Immunoblot showing MYCL, p21, p27, PARP1 and tRFP levels after 72 hr of 
doxycycline addition in H2141shMYCL cells. E, F. Growth curve of H2141shMYCL cells and percentage of dead cells in the presence or absence 
of doxycycline. *p<0.05, **p<0.01.
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both control cell lines (siCtrl), whereas such an increase 
was suppressed in the respective CDKN1A knocked-down 
(CDKN1Akd) cells (siCDKN1A in Figure 7A). The effect 
of Omomyc on growth suppression was significantly 
reduced in both cell lines by CDKN1A knockdown 
(Omomyc [+] vs [-]; N417omo siCtrl 54.6%, siCDKN1A 
71.1% - p<0.01, n=4; Lu135omo siCtrl 58.6%, siCDKN1A 
87.6% - p<0.01, n=4) ( Figure 7B). Consistently, G1 
arrest and the reduction in the size of cell aggregates 
were less evident after Omomyc induction in CDKN1Akd 
cells in comparison with siCtrl cells (Figure 7C and 7D). 
Therefore, the lack of CDKN1A induction hampered the 
effects of Omomyc on both cell growth and cell cycle 
progression. These results indicate that Omomyc induces 
G1 arrest through the activation of p21. However, the 
increase in sub-G1 fractions, as well as that in cleaved 
PARP1, caused by Omomyc was not affected in Lu135omo 
CDKN1Akd cells (Figure 7C and 7E).
Activation of CDKN1A requires high levels of 
TP73
Since increased levels of p21 were required for 
Omomyc-induced G1 arrest, we next investigated the 
molecular mechanism of CDKN1A activation in the 
absence of functional TP53. Since the binding of MYC 
to the promoter of CDKN1A through heterodimerization 
with MIZ1 is a well-established mechanism of CDKN1A 
repression by MYC [16, 29], we further investigated the 
effect of Omomyc on the binding of MYC and MIZ1 to 
the CDKN1A promoter by chromatin immunoprecipitation 
assay. The binding of MYC and MIZ1 to the CDKN1A 
promoter was confirmed; however, the binding of both 
proteins was not inhibited by Omomyc (Figure 8A and 8B).
TP53 belongs to a family of proteins, including 
TP63 and TP73, that increase the expression of similar 
groups of genes through the direct binding within their 
promoter regions (such as CDKN1A) which, in turns, 
induce cell cycle arrest, senescence, and/or apoptosis 
[30]. It was reported that MYC can repress TP73-
mediated transcriptional activation of CDKN1A, and 
that Prefoldin subunit 5 (PFDN5), also known as MYC 
binding protein 1 (MM1), antagonizes the inhibitory 
effect of MYC on TP73-dependent transactivation 
[31]. In SCLCs, expression of TP73 is relatively high 
[32], whereas expression of TP63 and MM1 is low 
(Supplementary Figure S3). Therefore, we evaluated 
TP73 protein levels in several representative cell lines. 
The amounts of TP73 were different among them 
(Figure 8C). Interestingly, TP73 was highly expressed 
in Lu135omo, where p21 was also highly induced by 
Omomyc. Therefore, we investigated whether p21 
Figure 6: G2/M arrest in H69omo induced by high levels of Omomyc expression. A, B. Red fluorescence intensity in H69omo 
induced for Omomyc-RFP expression with different concentrations of DX for 72 hr. Lu135omo cells were used as a representative cell line 
for the induction of Omomyc-RFP in other SCLC cell lines. C. Immunoblot analysis of Omomyc induction, PARP1 cleavage and p21 
levels. D, E. Effects of Omomyc on proliferation and death of H69omo. F. Cell cycle distribution and apoptotic fraction. The ratio of the 
number of cells in G1 phase versus S plus G2/M phases is shown.
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activation by Omomyc was dependent on TP73 in this 
cell line. Lu135omo cells were treated with a siRNA for 
TP73 and Omomyc was induced. The level of p21 up-
regulation by Omomyc was reduced in TP73 knockdown 
(TP73kd) cells (Figure 8D). Similar levels of Omomyc-
RFP were detected in control and TP73kd Omomyc-
induced cells, indicating that different p21 levels 
were not due to different Omomyc expression levels 
(Figure 8D and 8E). Then, the effects of Omomyc on 
cell growth and cell cycle profile were evaluated. The 
effect of Omomyc on growth reduction was decreased 
in TP73kd cells (Figure 8F) (Omomyc [+] vs [-], siCtrl 
71.1%, siTP73 90.9%, p<0.05, n=3). No differences 
on cell cycle distribution were detected either (Figure 
8G). These results indicate that high levels of TP73 are 
required for both p21 activation and G1 arrest induction 
by Omomyc in Lu135omo cells. Therefore, it is possible 
that Omomyc relieves the repressive role of MYC on the 
transcriptional activation of CDKN1A, which is activated 
in part by TP73 in SCLC cells.
DISCUSSION
Cell cycle arrest, differentiation, senescence or 
cell death have been reported to occur in cancer cells 
after MYC inhibition, through different molecular 
mechanisms [25,33–35]. It is likely that MYC inhibition 
affects different molecular pathways in cancer cells 
based on cell types, accumulated genetic alterations, 
and degree and mode of the inhibition. Here, we show 
that MYC inhibition by Omomyc, a dominant-negative 
MYC, suppresses the growth of SCLC cells with TP53 
and RB1 inactivation carrying MYC, MYCL, or MYCN 
amplification. Occurrence of cell cycle arrest in G1 phase 
was the consequences of MYC inhibition in most SCLC 
cell lines, indicating that MYC family genes amplified 
Figure 7: Downregulation of p21 impairs the Omomyc-induced G1 arrest. A. Immunoblot analysis for the knock-down of 
p21 in N417omo and Lu135omo cells. Cells were cultured with or without DX (+/- Omomyc). B. Number of cells after 72 hr (N417omo) or 
96 hr (Lu135omo) of culture. Data are shown as mean ± SD (n=4). P-values were calculated by unpaired two-tailed t-test. *p<0.01. C. Cell 
cycle distribution after after 72 hr (N417omo) or 96 hr (Lu135omo) of culture. x axis and y axis corresponds to DNA content and cell number, 
respectively. Sub-G1 gate is highlighted in green. The ratio of the number of cells in G1 phase versus S plus G2/M phases is shown. D. 
Representative images of floating cell aggregates after 72 hr (N417omo) or 96 hr (Lu135omo) of culture. Cells were photographed using 
phase-contrast microscopy at 5x magnitude. E. Cleavage of PARP1 in Lu135omo was evaluated by immunoblot analysis. Band intensity was 
quantified by densitometry and the ratio of cleaved/total (uncleaved+cleaved) was calculated.
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SCLC cells are addicted to MYC proteins function for 
their growth (Figure 9). Therefore, MYC family gene 
products appear promising targets for the treatment of 
SCLC patients. Since one of the three MYC family genes 
is amplified in a mutually exclusive manner in 20% of 
SCLCs, the development of therapeutic strategies against 
any MYC family members will be highly useful in the 
treatment of a significant fraction of SCLC.
Figure 8: Activation of CDKN1A by TP73 in a MYC-amplified SCLC cell line. A. Schematic representation of the CDKN1A 
gene and sequences amplified after chromatin immunoprecipitation (ChIP). Binding of MYC and MIZ1 has been reported in the proximity 
of P2 transcription starting site, spanning R2 region. B. ChIPs were carried out using chromatin obtained from Lu135omo cultured in the 
presence or absence of Omomyc for 48 hr using antibodies against MYC or MIZ1. R1 and R3 regions were used as negative controls of 
DNA: protein binding. C. Immunoblot analysis for the expression of TP73 in SCLC cells. D. Immunoblot analysis for the expression of 
TP73, p21, MYC, and Omomyc in TP73 knock-down Lu135omo cells 72 hr after Omomyc induction. Protein levels were normalized to the 
levels of tubulin. E. Flow cytofluorimetric analysis of Omomyc-RFP red fluorescence (575nm ±13) after 96 hr of DX addition. F. Number 
of cells after 96 hr from the induction of Omomyc. Data are shown as the mean ± SD (n=3). P-values were calculated by unpaired two-tailed 
t-test. *p<0.05. G. Cell cycle distribution. The ratio of the number of cells in G1 phase versus S plus G2/M phases is shown.
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Omomyc has been shown to suppress the growth of 
several cancer cells through its activity as a MYC inhibitor 
[22, 23, 25]. In this study, Omomyc also suppressed the 
growth of SCLC cells with high expression of MYC, 
MYCN or MYCL. Previously, Omomyc was shown to 
inhibit the binding of MYC and MYCN to MAX [18,20]. 
Here we show that Omomyc also inhibits the binding 
of MYCL to MAX in SCLC. These data strengthen the 
evidence indicating that Omomyc represents a common 
inhibitor for the interaction of MAX with all MYC 
proteins in vivo and further supports the utility of Omomyc 
as a therapeutic strategy for SCLC. In each SCLC cell line 
used in this study, only one of MYC proteins was highly 
expressed, but two or three MYC proteins are often co-
expressed in SCLC cells [14]. Therefore, Omomyc will 
be also highly effective in SCLC cells in which more than 
two MYC proteins are simultaneously expressed.
Omomyc consistently and remarkably increased the 
levels of p21, encoded by the CDKN1A gene, in most SCLC 
cell lines. Therefore, it is likely that Omomyc relieves the 
expression of genes whose transcription is repressed by MYC 
proteins. The present results further indicate that MYCL, 
similar to MYC and MYCN, also represses the transcription 
of the CDKN1A gene. However, Omomyc did not suppress 
the binding of MYC and MIZ1 to the promoter region of 
CDKN1A (Figure 8A and 8B), consistently with the previous 
observation [20]. It is possible that Omomyc substitutes 
MAX as a scaffold for the MYC-MIZ1 interaction. It is also 
possible that MAX is not strictly necessary for the formation 
of a MYC-MIZ1 functional complex to the CDKN1A 
promoter. The lack of Omomyc acrivity to inhibit the binding 
of MYC-MIZ1 complex to the CDKN1A promoter indicates 
that Omomyc interferes with another MYC-dependent 
mechanism of CDKN1A regulation, such as the activation of 
MYCLos non-coding RNA [36].
Inactivation of TP53 could interfere with therapeutic 
approaches based on MYC targeting, because of the opposite 
roles of MYC and TP53 in the regulation of p21. MYC 
hampers p21 functions in several contexts, for instance 
by repressing its transcription [37, 38], whereas TP53 is a 
transcriptional activator of CDKN1A [29, 39]. Therefore, 
MYC inhibition would allow the TP53-dependent 
activation of CDKN1A, which in turns leads to cell cycle 
arrest and apoptosis. However, the TP53 gene is mutated 
in all the SCLC cell lines used in this study, indicating that 
p21 up-regulation occurs in a TP53-independent manner. 
Therefore, we pursued the possible involvement of TP73, 
another TP53 family protein, in the up-regulation of p21 in 
SCLC cells after Omomyc induction. At least in the Lu135 
cell line, TP73 was required for the activation of p21 and 
for induction of G1 arrest (Figure 8 and Figure 9). It was 
reported that MYC abrogates TP73-mediated activation of 
TP53-target genes by direct protein:protein interaction [31, 
40]. Therefore, it is possible that MYC also abrogates the 
TP73 mediated transcriptional activation of the CDKN1A 
gene in a subset of SCLCs. However, cell growth was 
also reduced after knockdown of TP73 in cells without 
Omomyc, indicating that high levels of TP73 are required 
for cell survival (Figure 8D). Previously, it was reported 
that TP73 alpha has an anti-apoptotic effect in SCLC cells, 
whereas TP73 beta has a pro-apoptotic effect [41]. Since 
both isoforms are targeted by the treatment with siRNA, 
it was likely that apoptosis was induced by the reduced 
TP73 alpha expression independently of Omomyc (Figure 
8E). In this study, we found that different levels of TP73 
are expressed among the SCLC cell lines. A recent study 
Figure 9: MYC, MYCL and MYCN inhibition by Omomyc induces cell cycle arrest through the activation of p21, in 
some cases through the TP73 pathway.
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revealed that TP73 is mutated, deleted and rearranged in 
~13% of SCLC cases [42]. Therefore, the effects of MYC 
inhibition could vary according to the status of the TP73 
gene and its expression. Further studies are needed to clarify 
the interconnection between MYC proteins and TP73 in 
SCLC cells.
Occurrence of G1 arrest and apoptosis by MYC 
inhibition in TP53 inactivated cells have been reported in 
RB1 wild-type cells with high levels of MYC or MYCN 
expression [35, 43, 44]. Moreover, in TP53 inactivated 
melanoma cells, inhibition of RB1 was reported to prevent 
the occurrence of apoptosis induced by MYC inhibition 
[45]. In this study, both growth arrest and apoptosis 
were induced by MYC inhibition in SCLC cells with 
RB1 mutations. CDKIs, such as p21 and p27, are well 
known modulators of RB1 phosphorylation through 
the inhibition of the activity of CDK-cyclin complexes: 
CDKIs induce cell cycle arrest by maintaining RB family 
proteins, RB1, p107 (RBL1) and Rb2/p130 (RBL2), in 
a hypophosphorylated state, which in turns repress the 
transcription of E2F-target genes and block transition from 
G1 to S phase [26, 27]. Since RB1 is genetically inactivated 
and RBL2 has been reported to be transcriptionally 
repressed in SCLC cells, it is possible that G1 arrest was 
mediated by the hypophosphorylation of p107 [46–48]. 
Alternatively, it is also possible that p21 directly interacts 
with E2F1 and PCNA, and these interactions induce G1 
arrest in SCLC cells without functional RB family proteins 
[37]. A recent study also revealed that RBL1 and RBL2 are 
mutated in a subset of SCLCs together with TP53 and RB1 
and mutually exclusively with each other and with TP73 
[42]. Indeed, in two of the nine SCLC cell lines examined 
in this study, H69 and H345, G2/M arrest, but not G1 
arrest, was induced by Omomyc induction. Therefore, it is 
likely that the effect of Omomyc could be different among 
SCLCs due to accumulated genetic alterations of cell cycle 
regulators other than TP53 and RB1.
In summary, we demonstrated here that MYC 
inhibition by Omomyc induces cell cycle arrest in all 
the nine SCLC cell lines tested. The results strongly 
indicate that SCLC cells are addicted to MYC proteins 
for their growth and, therefore, are highly sensitive to 
MYC inhibition for their growth suppression in spite 
of the presence of TP53 and RB1 genetic inactivation. 
Accordingly, it was concluded from this study that MYC 
inhibition would be a promising therapeutic strategy for 
a significant fraction of SCLC, an aggressive cancer with 
extremely high mortality rate.
MATERIALS AND METHODS
Cell cultures
SCLC cell lines, N417, H2141, HCC33, H69, H345 
and H2107, were obtained from Dr. J. D. Minna (University 
of Texas Southwestern, Dallas), H526 from Dr. C. C. Harris 
(NCI, Bethesda), Lu135 from Dr. T. Terasaki (National 
Cancer Center, Tokyo, Japan), and H446 from the Japanese 
Collection of Research Bioresources. Cells were cultured 
in RPMI supplemented with L-Glutamine and HEPES 
supplemented with 10% tetracycline-free FBS (Clontech) 
with 5% CO2 at 37°C.
Lentivirus preparation, infection and selection of 
infected cells
Construction of the lentiviral vector pTRIPZ-
Omomyc-RFP for the inducible expression of a 
Omomyc-RFP fusion protein was described previously 
[25]. A pTRIPZ-shMYCL-RFP expression vector, 
V2THS197161, was purchased from GE Healthcare 
Dharmacon. For lentivirus production, 293T cells were 
plated and medium containing 25μM chloroquine was 
added on the following day. Two hours later, cells were 
transfected with pTRIPZ-Omomyc-RFP or pTRIPZ-
shMYCL-RFP, plus psPAX2 and pMD.G2, using the 
calcium phosphate method. After 16 hr, the medium was 
replaced with RPMI supplemented with tetracycline-free 
FBS. After 24 hr and 48 hr, first and second aliquots of 
media were collected and filtered with a 0.45μm PVDF 
filter. Cells were infected with the virus for 24 hr with the 
addition of polybrene (2μg/ml). Puromycin was added to 
kill non-infected cells and to maintain optimal plasmid 
integration.
Cell growth assays
Cell growth assays were performed with a 
modification of serial cultivation method [49]. Briefly, 
cells at the concentration of 5.0x104/ml (H446), 1.0x105/
ml (N417, Lu135, H2141, HCC33, H526, H69, H345), 
or 2.0x105/ml (H2107) were plated and replated at the 
same density every 3 days (N417, H69), 4 days (Lu135, 
H446, H2141, HCC33, H526, H345), or 5 days (H2107) 
for two passages. Number of days between each passage 
was chosen to allow at least one population doubling 
in untreated cells. Cell number and viability were 
determined by dye exclusion trypan blue assay using Cell 
Countess® (Life Technologies). Population doubling 
level (PDL) was calculated using the formula PDL = log2 
(Nf/Ni), where Ni is the initial number and Nf is the final 
number of cells.
Transfections
siRNA was transfected using RNAiMAX (Life 
Technologies). Concentrations of siRNA and RNAiMAX 
were 50nM and 2.5μl/ml, respectively. siRNA sequences 
(ON-TARGETplus siRNA, GE Dharmacon) used were: 
MYC (pool of 2 sequences: J-003282-25, J-003282-26), 
CDKN1A (J-003471-12), and TP73 (J-003331-10). After 
6 hr, media was changed and, if required, doxycycline 
was added. A non-targeting siRNA was used as control 
Oncotarget31025www.impactjournals.com/oncotarget
(D-001600-01, GE Dharmacon). Control sequence, 
containing DY-547 red fluorescent oligonucleotides, 
was used to estimate transfection efficiency. Cells were 
analyzed after 72-96 hr of transfection.
Cell cycle analysis
Cells were centrifuged at 200g for 5 min, washed 
in PBS, counted, and fixed with 70% ice-cold ethanol. 
Fixed cells were centrifuged at 1000g for 5 min, washed, 
resuspended in PBS containing 0.1% Triton X-100, 
0.2mg/ml RNase A and 1μg/ml DAPI, and analyzed with 
FACS Fortessa (Beckton Dickinson). At least 20,000 
events were tested to evaluate cell cycle status. The 
percentage of cells in sub-G1 (<2n) was calculated based 
on the DNA content, and those in G1, S, and G2/M were 
calculated in living cell population based on their DNA 
content/FSC-A profile.
Western blot analysis
Cells were lysed in buffer (50mM TRIS, 0.5% 
sodium deoxycholate, 1.0% NP-40, 0.1% SDS, 150mM 
NaCl, 2mM EDTA) supplemented with protease 
inhibitors (Roche). Lysates (15-30μg) were resolved by 
SDS-PAGE, transferred to nitrocellulose membranes, 
and probed with the following antibodies: MYC (sc-40, 
Santa Cruz), MYCL (#AF4050, R&D), MYCN (#9405, 
Cell Signaling), Omomyc, p21 (#2947, Cell Signaling), 
p27 (sc-1641, Santa Cruz), p16 (51-1325GR, BD), PARP1 
(#9542, Cell Signaling), TP73 (sc-7957, Santa Cruz), 
α-Tubulin (CP06, CalBiochemicals). Membranes were 
then incubated with a peroxidase-conjugated antibody. 
Enhanced chemiluminescence was performed according 
to manufacturer’s instructions (Western Lightning Plus, 
Perkin Elmer).
Co-immunoprecipitation assay
Co-immunoprecipitation assays were performed 
according to manufacturer’s instructions (Dynabeads 
Protein A, Life Technologies). Whole cell extracts were 
obtained by incubating cells in 1.0% NP-40, 250mM 
NaCl, 50mM Tris-HCl (pH 7.4), 5mM EDTA, 0.02% 
NaN3 buffer supplemented with protease and phosphatase 
inhibitors (Roche). Extracts were pre-cleared with 20μl of 
beads for 1 hr, and 0.5mg of proteins were incubated for 
1 hr with 50μl of beads pre-incubated with 1μg/ml of the 
following antibodies: anti-tRFP (AB234, Evrogen), anti-
MYC (N-262, Santa Cruz), anti-MYCL (AF4050, R&D 
Systems), anti-MAX (C-17, Santa Cruz Biotechnology). 
Samples were washed with PBS containing 0.1% 
Tween-20, eluted with Nu-Page LDS and Reducing 
Sample Buffers (Life Technologies), and loaded on a 10% 
acrylamide gel.
Cromatin immunoprecipitation assay
ChIP assays were carried out according to 
manufacturer’s instructions (ChIP-IT Express Enzymatic 
Kit, Active Motif). The following antibodies were used: 
anti-MYC (N-262, Santa Cruz) or anti-MIZ1 (N-17, Santa 
Cruz). For the amplification of R1, R2 and R3 regions, 
the following previously reported primers were used: 
5’-AGCAGGCTGTGGCTCTGATT-3’ (R1, Forward), 
5’-CAAAATAGCCACCAGCCTCTTCT-3’ (R1, Reverse), 
5’-ACCGGCTGGCCTGCTGGAACT-3’ (R2, Forward), 
5’-TCTGCCGCCGCTCTCTCACCT-3’ (R2, Reverse), 
5’-TCTGTCTCGGCAGCTGACAT-3’ (R3, Forward), 5’- 
ACCACAAAAGATCAAGGTGAGTGA-3’ (R3, Reverse). 
Each sample was used as template in Real-Time PCR to 
evaluate the enrichment of R1, R2 or R3 regions.
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